SCHEMBL16095457

SCHEMBL16095457

CCCCOC(=O)C1(C)CC(OS(=O)(=O)C(F)(F)F)=CC(C)(C)O1

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 3/20 0.34
▸ STS P08842 7/20 0.32
▸ DRD2 P14416 1/20 0.30
▸ HTR1D P28221 1/20 0.30
▸ DRD3 P35462 1/20 0.30
▸ HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16094883 0.83 HSD11B1 (0.32) STSHSD11B1
SCHEMBL18696984 0.81 HSD11B1 (0.31) HSD11B1
SCHEMBL16118390 0.76 — —
SCHEMBL30990702 0.72 DRD2 (0.33) STSDRD2DRD3
SCHEMBL16118391 0.71 — —
SCHEMBL16094973 0.70 PSEN1 (0.34) PSEN1
SCHEMBL17448820 0.70 PSEN1 (0.36) PSEN1
SCHEMBL30509699 0.70 LMNA (0.36) STSDRD2DRD3
SCHEMBL16887646 0.69 BACE1 (0.33) STSDRD2HTR1DDRD3
SCHEMBL29698862 0.66 LMNA (0.39) STSDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11214566-B2 Substituted pyridine derivatives useful as C-FMS kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-01-04 — — US disclosed
US-20200399254-A1 Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-12-24 — — US disclosed
US-10800764-B2 Substituted pyridine derivatives useful as C-FMS kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-10-13 — — US disclosed
US-20180346454-A1 Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors JANSSEN PHARMACEUTICA NV (BE) 2018-12-06 — — US disclosed
US-10071991-B2 Substituted pyridine derivatives useful as c-fms kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2018-09-11 — — US disclosed
EP-3284742-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS Janssen Pharmaceutica NV (BE) 2018-02-21 — — EP disclosed
EP-2970232-B1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-02-14 — — EP disclosed
US-20170158678-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-08 — — US disclosed
US-20170158678-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-08 — — US disclosed
US-9611259-B2 Substituted pyridine derivatives useful as C-FMS kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-04-04 — — US disclosed
US-9611259-B2 Substituted pyridine derivatives useful as C-FMS kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-04-04 — — US disclosed
US-20160016942-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-01-21 — — US disclosed
US-20160016942-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-01-21 — — US disclosed
EP-2970232-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP disclosed
WO-2014151258-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO disclosed
WO-2014151258-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016942-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS FLT3, ABL1, FES PSEN1 3876/4885STS 2312/4885DRD2 4584/4885
US-10071991-B2 Substituted pyridine derivatives useful as c-fms kinase inhibitors FLT3, ABL1, FES PSEN1 3876/4885STS 2312/4885DRD2 4584/4885
US-20180346454-A1 Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors FLT3, ABL1, FES PSEN1 3876/4885STS 2312/4885DRD2 4584/4885
US-20200399254-A1 Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors FLT3, ABL1, FES PSEN1 3876/4885STS 2312/4885DRD2 4584/4885
US-10800764-B2 Substituted pyridine derivatives useful as C-FMS kinase inhibitors FLT3, ABL1, FES PSEN1 3876/4885STS 2312/4885DRD2 4584/4885
US-11214566-B2 Substituted pyridine derivatives useful as C-FMS kinase inhibitors FLT3, ABL1, FES PSEN1 3876/4885STS 2312/4885DRD2 4584/4885
US-20170158678-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS FLT3, ABL1, FES PSEN1 3876/4885STS 2312/4885DRD2 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback